According to a recent LinkedIn post from Colossal Biosciences, the company is positioning the bluebuck (Hippotragus leucophaeus) as its latest de‑extinction project, emphasizing the animal’s distinct appearance and historical presence in South Africa. The post describes the species as having been driven extinct around 1800 and suggests Colossal is working to develop technologies that could enable its revival.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights Colossal’s continued expansion of its de‑extinction pipeline beyond earlier high‑profile species, which may indicate a strategy to build a diversified portfolio of genetic and reproductive technologies. For investors, this focus could signal long‑term bets on platform applications in conservation biology, genomics, and adjacent commercial fields, though timelines, regulatory pathways, and monetization models remain highly uncertain.
By spotlighting a lesser‑known extinct species with a visually distinctive profile, the post also appears aimed at sustaining public and partner interest in de‑extinction as a category. This type of engagement may help the company attract research collaborations, philanthropic or government funding, and future strategic partnerships, factors that could influence its capital needs and valuation trajectory over time.